Please login to the form below

Not currently logged in
Email:
Password:

Boehringer/ Ablynx candidate for Alzheimer's

Ablynx has announced that Boehringer Ingelheim has selected a Nanobody lead candidate for further development for treating Alzheimer's disease

Ablynx has announced that Boehringer Ingelheim has selected a Nanobody lead candidate for further development for the treatment of Alzheimer's disease.

This is the first lead candidate emerging from the Alzheimer's disease collaboration between Ablynx and Boehringer Ingelheim, and will result in a €2m milestone payment to Ablynx.

In January 2007, Boehringer Ingelheim and Ablynx announced that they had entered into a worldwide research and licensing agreement to discover and develop new therapies for Alzheimer's disease using Ablynx's Nanobodies, worth a possible $265m in milestone payments plus undisclosed royalties. Boehringer Ingelheim is solely responsible for the development, manufacture and commercialisation of any products resulting from the research collaboration.

"Ablynx's delivery of this potentially 'first-in-class' Nanobody candidate for the treatment of Alzheimer's disease highlights the speed at which we progressed from initiation of the discovery programme in 2007 to this stage of development for a very challenging target," said Dr Edwin Moses, CEO and chairman of Ablynx.

Moses added: "This lead candidate demonstrates the power of the Nanobody platform in addressing a complex disease such as Alzheimer's."

24th May 2010

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Cogora

Cogora has been a leader in healthcare publishing for over 30 years and has become one of the leading full-service...

Latest intelligence

Theresa Heggie
Alnylam’s big moment: bringing groundbreaking RNAi drugs to Europe
Theresa Heggie talks about the biotech’s 16-year path to market, and the promise of its ‘gene silencing’ medicines...
patients
Retaining reader value in plain language summaries of clinical studies
Balancing the risk of misinterpretation with the public’s ability to understand simplified plain-language summaries...
Can we talk about the ego-bias and chemicals influencing your target audience’s behaviour?
Over the Summer, the Page & Page team became fascinated by two books on this very subject. Two books from one author, Dean Burnett, an eminent neuroscientist, lecturing at Cardiff...

Infographics